Skip to content

Role of immune suppressing eye drops in corneal infection caused by fungus

Fungal ulcer Augmented treatment with Natamycin and Cyclosporine Trial ? Pilot study

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093522
Enrollment
150
Registered
2025-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H160- Corneal ulcer

Interventions

Intervention1: Fungal ulcer treated with antifungas with 0.1% cyclosporine or 2% cyclosporine: In addition to conventional antifungal eye drops, 0.1% or 2% cyclosporine eye drops will be used as 4 tim

Sponsors

Aravind Eye Hospital
Lead Sponsor
Francis I Proctor foundation
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Smear or culture positive for fungal keratitis, of any size and Visual acuity of worse than 6/12 and better than 3/60

Exclusion criteria

Exclusion criteria: Impending perforation/perforation/endophthalmitis Evidence of acanthamoeba by stain/herpetic keratitis by history or exam/bacterial mixed infection History of corneal scar in the affected eye and best corrected visual acuity worse than 6/60 in other eye Bilateral ulcers Previous penetrating keratoplasty Known allergy to study medications (cyclosporine or preservative) Previous history of topical steroid/native medication use

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity at 3 months between the placebo and intervention groupsTimepoint: Best corrected visual acuity at 3 months between the placebo and intervention groups

Secondary

MeasureTime frame
Scar sizeTimepoint: 3 months;Corneal perforation and need for therapeutic keratoplastyTimepoint: 3 months

Countries

India

Contacts

Public ContactJosephine Christy

Aravind Eye Hospital, Pondicherry, India

josyfred@gmail.com9994549584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026